The MAPT H1/H2 Haplotype — An Ancient Inversion That Shapes Tauopathy Risk
About 3 million years ago, a 900-kilobase inversion occurred on chromosome 17q21 | This inversion created two distinct haplotype clades that have been recombinationally suppressed since, accumulating independent sequence variations, creating two distinct evolutionary lineages of the microtubule-associated protein tau (MAPT) gene: H1 and H2. This SNP, rs17649553, is one of several markers that can distinguish between these two haplotypes, which have profoundly different effects on the risk of developing neurodegenerative diseases involving abnormal tau protein deposits.
The MAPT gene encodes tau, a protein primarily expressed in neurons that stabilizes microtubules and supports axonal transport | Microtubules are the cell's internal transportation system, and tau helps maintain their structure. When tau becomes abnormally phosphorylated and aggregates, it forms neurofibrillary tangles — pathological hallmarks of tauopathies including Alzheimer's disease, progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), Pick's disease, and some forms of Parkinson's disease and frontotemporal dementia (FTD).
The Haplotype Structure
Because of the ancient inversion, H1 and H2 exist in complete linkage disequilibrium across nearly 900kb | Any SNP in this region can tag the haplotype, as recombination between them has been suppressed for millions of years. The H1 haplotype is evolutionarily dynamic and contains numerous subhaplotypes (H1a, H1b, H1c, etc.), while H2 is more homogeneous. Population distribution is striking: H2 is rare in Africans, almost absent in East Asians, but found at approximately 20% frequency in Europeans | This population-specific distribution suggests selection pressure in European populations.
The Evidence for Parkinson Disease
A 2007 study of 1,762 Parkinson's disease patients and 2,010 controls found a robust association between the H1/H1 diplotype and PD risk (OR 1.46, 95% CI 1.25-1.69, p = 8×10⁻⁷) | The effect was evident in both familial and sporadic subgroups, men and women, and early- and late-onset disease. A meta-analysis of 23 Caucasian case-control series (7,736 patients, 9,339 controls) estimated an overall OR of 0.78 for H2 versus H1 | This suggests H2 may be protective against Parkinson's disease.
Progressive Supranuclear Palsy and Other 4R Tauopathies
The association is even stronger for PSP. The H1 haplotype is found in approximately 94% of PSP patients compared to around 78% in healthy adults | Nearly all PSP patients are H1 homozygotes, though H1 appears necessary but not sufficient to cause disease. PSP is a rare atypical parkinsonian disorder characterized by vertical supranuclear gaze palsy, unprovoked falls, axial rigidity, and cognitive decline, with predominant accumulation of 4-repeat tau in neurons and glia | The 4R:3R tau isoform ratio appears critical in PSP pathogenesis.
Corticobasal degeneration and Alzheimer's disease also show H1 associations, though the specific subhaplotypes involved differ. The H1c subhaplotype, tagged by rs242557, is specifically associated with increased Alzheimer's disease risk in APOE ε4 non-carriers | Different H1 subhaplotypes confer risk for different tauopathies.
The Pick's Disease Paradox
In a striking reversal, a 2024 study of 338 pathologically confirmed Pick's disease cases found the H2 haplotype associated with increased risk | This is opposite to the protective effect seen in PSP and CBD. Pick's disease is a 3-repeat tauopathy characterized by Pick bodies in the frontal and temporal lobes. This finding suggests the H1/H2 polymorphism may affect the balance of 3R and 4R tau isoforms through alternative splicing of exon 10 | H1 may promote 4R tau, while H2 may favor 3R tau.
Frontotemporal Dementia
The majority of genetic FTD is caused by mutations in C9ORF72, MAPT, or GRN genes | About 10-20% of all FTD cases are genetic. While pathogenic mutations in MAPT cause familial FTD with autosomal dominant inheritance, the common H1 haplotype also contributes to sporadic FTD risk, particularly the H1c subclade | A 2024 GWAS of 4,685 sporadic FTD cases found genome-wide significant association at the MAPT locus (p = 2.5×10⁻¹²).
Mechanism and Splicing
Studies using whole-locus genomic MAPT expression vectors demonstrate that intronic variants like rs1800547 and rs17651213 regulate haplotype-specific splicing of exon 3 | The splicing factors hnRNP F and hnRNP Q mediate this haplotype-specific regulation. The H2 haplotype is associated with lower total MAPT expression and altered isoform ratios compared to H1 | This may explain the differential tauopathy risk profiles. Specifically, H1 appears to favor production of 4R tau isoforms, which may explain its association with 4R tauopathies like PSP and CBD.
Aging and Bradykinesia
Even in neurologically healthy older adults, the H2 haplotype is associated with age-related motor impairment, particularly bradykinesia (slowness of movement) | This suggests MAPT variants influence aging-related functional decline independent of clinical disease. The mechanism appears distinct from classical Parkinson's disease and may involve cortico-nigro-striatal pathways different from those typically affected in PD.
Interactions
The H1/H2 haplotype interacts with other genetic risk factors. In Huntington's disease (a secondary tauopathy), H2 carriers show more rapid cognitive decline compared to H1 carriers | This suggests tau pathology contributes to HD progression. In APOE ε4 non-carriers, the MAPT H1 haplotype becomes a more prominent risk factor for Alzheimer's disease | This suggests genetic interactions between the two major AD risk loci.
The relationship between MAPT haplotypes and alpha-synuclein pathology (the hallmark of Parkinson's disease) remains incompletely understood, though interaction analyses have not found evidence of epistatic effects between SNCA and MAPT loci | The two risk factors appear to act independently.
All Genotypes
One copy of each haplotype with intermediate tauopathy risk
You carry one copy of the H1 haplotype and one copy of the H2 haplotype. This genotype is associated with lower risk for progressive supranuclear palsy, corticobasal degeneration, and Parkinson's disease compared to H1/H1 individuals, but slightly higher risk than H2/H2. About 32% of people of European descent share this genotype. Meta-analyses suggest an odds ratio around 1.0-1.2 for Parkinson's disease compared to H2/H2 carriers, making your risk intermediate between the two homozygous genotypes. The presence of one H2 copy appears partially protective for 4-repeat tauopathies.
One copy of each haplotype with intermediate tauopathy risk
You carry one copy of the H1 haplotype and one copy of the H2 haplotype. This genotype is associated with lower risk for progressive supranuclear palsy, corticobasal degeneration, and Parkinson's disease compared to H1/H1 individuals, but slightly higher risk than H2/H2. About 32% of people of European descent share this genotype. Meta-analyses suggest an odds ratio around 1.0-1.2 for Parkinson's disease compared to H2/H2 carriers, making your risk intermediate between the two homozygous genotypes. The presence of one H2 copy appears partially protective for 4-repeat tauopathies.
Two copies of the H1 haplotype associated with increased tauopathy risk
You carry two copies of the H1 haplotype, the ancestral and more common form of the MAPT gene region. This genotype is associated with increased risk for several neurodegenerative diseases involving abnormal tau protein, particularly progressive supranuclear palsy (PSP), corticobasal degeneration, and Parkinson's disease. About 64% of people of European descent share this genotype. The H1/H1 genotype is found in approximately 94% of PSP patients versus 64% of the general population, translating to a 1.5-fold increased relative risk for Parkinson's disease. However, it's important to understand that most H1/H1 individuals never develop these conditions — H1 appears necessary but not sufficient for disease. The absolute risk remains low, as PSP affects only about 6 per 100,000 people.
Two copies of the H1 haplotype associated with increased tauopathy risk
You carry two copies of the H1 haplotype, the ancestral and more common form of the MAPT gene region. This genotype is associated with increased risk for several neurodegenerative diseases involving abnormal tau protein, particularly progressive supranuclear palsy (PSP), corticobasal degeneration, and Parkinson's disease. About 64% of people of European descent share this genotype. The H1/H1 genotype is found in approximately 94% of PSP patients versus 64% of the general population, translating to a 1.5-fold increased relative risk for Parkinson's disease. However, it's important to understand that most H1/H1 individuals never develop these conditions — H1 appears necessary but not sufficient for disease. The absolute risk remains low, as PSP affects only about 6 per 100,000 people.
Two copies of H2 haplotype protective against common tauopathies but increased Pick's disease risk
You carry two copies of the H2 haplotype, the more recent evolutionary variant found primarily in populations of European descent. This genotype is associated with reduced risk for progressive supranuclear palsy, corticobasal degeneration, and Parkinson's disease — the most common tauopathies. Only about 4% of people of European descent carry this genotype, making it relatively rare. The H2/H2 genotype is strongly underrepresented in PSP (found in <1% of patients versus 4% of controls) and associated with a meta-analytic odds ratio of about 0.78 for Parkinson's disease, suggesting moderate protection. However, for Pick's disease specifically, H2/H2 is associated with increased risk compared to H1/H1.
Two copies of H2 haplotype protective against common tauopathies but increased Pick's disease risk
You carry two copies of the H2 haplotype, the more recent evolutionary variant found primarily in populations of European descent. This genotype is associated with reduced risk for progressive supranuclear palsy, corticobasal degeneration, and Parkinson's disease — the most common tauopathies. Only about 4% of people of European descent carry this genotype, making it relatively rare. The H2/H2 genotype is strongly underrepresented in PSP (found in <1% of patients versus 4% of controls) and associated with a meta-analytic odds ratio of about 0.78 for Parkinson's disease, suggesting moderate protection. However, for Pick's disease specifically, H2/H2 is associated with increased risk compared to H1/H1.